Aquestive Therapeutics, Inc. (AQST) Operating cash flow 2017–2025
Aquestive Therapeutics, Inc. (AQST) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$52.4MFY2025 · since FY2017: $5.8M → -$52.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$52.4M | -46.6% |
| FY2024 | -$35.8M | -460.5% |
| FY2023 | -$6.4M | +35.0% |
| FY2022 | -$9.8M | +70.2% |
| FY2021 | -$33.0M | +27.5% |
| FY2020 | -$45.5M | +24.5% |
| FY2019 | -$60.2M | -363.5% |
| FY2018 | -$13.0M | -323.1% |
| FY2017 | $5.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice